Pfizer's RSV Vaccine Abrysvo Demonstrates Sustained High Efficacy Through Two Respiratory Seasons

Mar 01, 2024 10:01 CST Updated 10:01

Pfizer

Pharmaceutical R&D Developer

February 29,PfizerAnnouncement: RSV VaccineAbrysvoFor elderly people aged 60 years and abovePopulation-based Prevention of RSV-associated Lower Respiratory Tract Disease (RSV-LRTD)The Key Phase IIIRENOIR Study(NCT05035212) has made positive progress, showing high protective efficacy against both RSV A and RSV B subtypes over two epidemic seasons after a single vaccination.

Specific research results show that, at the time of testing during the second epidemic season,AbrysvoThe efficacy of preventing RSV-related lower respiratory tract diseases (with three or more symptoms) is 77.8%; the vaccine's protective efficacy after the first epidemic season is 88.9%, indicatingAbrySVO still has lasting protective efficacy after two epidemic seasons.

After the second epidemic season,AbrySVO for three or more symptomsRSV A and B typesPreventionConsistent efficacy, both ≥80%.In the case of two or more mild symptomsofLower Respiratory Tract DiseasesThePreventive EfficacyIs also ongoing，ByThe First Season65.1%After the end of Season 255.7%。

Moreover, after approximately 16.4 months of monitoring,AbrySVO for RSV-The protective efficacy of LRTD (three or more symptoms) was 81.5%. No new adverse event reports were observed in the study.

AbrySVO was approved by the FDA for use in people aged 60 and above by the end of May 2023, and three months later received another FDA approval to expand its indications, providing vaccination for pregnant women to protect newborns. Although in its first year on the market,AbrySVO generated $890 million in sales, but lagged behind the product fromGSKVaccineArexvySales (approximately 1.5 billion USD).

Besides, Pfizer'sAbrySVO will also cooperate withSanofi/AstraZenecaCo-developed RSV MonoclonalAnti-BeyfortusLaunch competition.Beyfortus was approved for marketing by the FDA in July 2023.Used to prevent lower respiratory tract diseases caused by respiratory syncytial virus in infants and young children, with last year's sales reaching 547 million euros (592 million US dollars).

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprinting, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content.PharmaCubeShall not be liable for any loss incurred by any party as a result of using the content of this article.